Literature DB >> 7520377

The immunoreactive region in a novel autoantigen contains a nuclear localization sequence.

D B Bloch1, D Rabkina, T Quertermous, K D Bloch.   

Abstract

Antibodies in the serum of patients with autoimmune diseases have been used to identify human autoantigens. Because autoantibodies often recognize active sites within corresponding protein antigens, autoantibodies have facilitated the functional characterization of these polypeptides. In the present study, serum from a patient with Sjögren's syndrome was used to identify a novel autoantigen which was designated Ge-1. Using the patient's serum, a 4.8-kb cDNA encoding Ge-1 was identified. Fragments of the cDNA were ligated into prokaryotic expression vectors, expressed in Escherichia coli, and used to produce recombinant Ge-1 fusion proteins. Fusion proteins containing different portions of Ge-1 were used to identify a 58 amino acid immunoreactive region within the protein. This immunoreactive region contained the protein's putative nuclear localization sequence (NLS). To demonstrate that the immunoreactive region was capable of functioning as a NLS, a eukaryotic expression plasmid was constructed to encode the immunoreactive region fused to the cytoplasmic protein, chicken muscle pyruvate kinase. After transfection of this plasmid into COS-1 cells, the fusion protein was detected in the nucleus. The presence of the NLS motif within the immunoreactive region of Ge-1 and other nuclear autoantigens suggests that the NLS may be a target of human autoantibodies.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7520377     DOI: 10.1006/clin.1994.1156

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  7 in total

1.  Processing body autoantibodies reconsidered.

Authors:  Donald B Bloch; Tod Gulick; Kenneth D Bloch; Wei-Hong Yang
Journal:  RNA       Date:  2006-05       Impact factor: 4.942

2.  Ge-1 is a central component of the mammalian cytoplasmic mRNA processing body.

Authors:  Jiang Hong Yu; Wei-Hong Yang; Tod Gulick; Kenneth D Bloch; Donald B Bloch
Journal:  RNA       Date:  2005-12       Impact factor: 4.942

3.  Clinical and serological features of patients with autoantibodies to GW/P bodies.

Authors:  Rahima A Bhanji; Theophany Eystathioy; Edward K L Chan; Donald B Bloch; Marvin J Fritzler
Journal:  Clin Immunol       Date:  2007-09-17       Impact factor: 3.969

4.  RNA-associated protein 55 (RAP55) localizes to mRNA processing bodies and stress granules.

Authors:  Wei-Hong Yang; Jiang Hong Yu; Tod Gulick; Kenneth D Bloch; Donald B Bloch
Journal:  RNA       Date:  2006-02-16       Impact factor: 4.942

5.  LMKB/MARF1 localizes to mRNA processing bodies, interacts with Ge-1, and regulates IFI44L gene expression.

Authors:  Donald B Bloch; Pingcheng Li; Emily G Bloch; Daniel F Berenson; Rita L Galdos; Pankaj Arora; Rajeev Malhotra; Connie Wu; Weihong Yang
Journal:  PLoS One       Date:  2014-04-22       Impact factor: 3.240

6.  Crosstalk between Edc4 and mammalian target of rapamycin complex 1 (mTORC1) signaling in mRNA decapping.

Authors:  Hazir Rahman; Muhammad Qasim; Michael Oellerich; Abdul R Asif
Journal:  Int J Mol Sci       Date:  2014-12-12       Impact factor: 5.923

7.  Establishment of international autoantibody reference standards for the detection of autoantibodies directed against PML bodies, GW bodies, and NuMA protein.

Authors:  Bing Zheng; Rodrigo A Mora; Marvin J Fritzler; Minoru Satoh; Donald B Bloch; Ignacio Garcia-De La Torre; Katherine Boylan; Kathryn Kohl; Mark H Wener; Luis E C Andrade; Edward K L Chan
Journal:  Clin Chem Lab Med       Date:  2020-08-10       Impact factor: 3.694

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.